A Randomized Phase II Study of Irinotecan, 5-Fluorouracil and Folinic Acid (FOLFIRI) With or Without the Addition of an Endothelin Receptor Antagonist in Patients With Metastatic Colorectal Cancer After Failure of Oxaliplatin-Containing Chemotherapy.

Trial Profile

A Randomized Phase II Study of Irinotecan, 5-Fluorouracil and Folinic Acid (FOLFIRI) With or Without the Addition of an Endothelin Receptor Antagonist in Patients With Metastatic Colorectal Cancer After Failure of Oxaliplatin-Containing Chemotherapy.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 29 Mar 2016

At a glance

  • Drugs Zibotentan (Primary) ; Fluorouracil; Folinic acid; Irinotecan
  • Indications Colorectal cancer
  • Focus Pharmacogenomic; Therapeutic Use
  • Acronyms FOLFERA
  • Most Recent Events

    • 09 Feb 2013 New source identified and integrated (European Clinical Trials Database; EudraCT2009-012151-23).
    • 26 Jan 2013 Primary endpoint 'Progression-free-survival-duration' has not been met.
    • 26 Jan 2013 Status changed from active, no longer recruiting to discontinued. This study was terminated before the planned number of patients (n=122) were recruited due to a lack of efficacy of zibotentan in two other tumour types.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top